Cytokeratin 17 Antibody (E3): sc-58726

Cytokeratin 17 Antibody (E3) is a mouse monoclonal IgG2b antibody that detects Cytokeratin 17 in mouse, rat, and human samples through applications such as western blotting (WB), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Cytokeratin 17 is a crucial member of the Cytokeratin subfamily of intermediate filament proteins, consisting of 432 amino acids, and is predominantly expressed in the basal cells of complex epithelia, including the nail bed, hair follicle, and sebaceous glands. Anti-Cytokeratin 17 antibody (E3) plays a vital role in studying structural integrity and function of epithelial tissues. Cytokeratin 17 is involved in regulating cell growth and size by interacting with the adaptor protein 14-3-3-sigma, which mediates protein synthesis. Mutations in the gene encoding Cytokeratin 17 can lead to impaired protein translation and reduced keratinocyte size, which is associated with decreased Akt/mTOR signaling activity. Cytokeratin 17 (E3) antibody serves as a valuable marker for various conditions, including cervical stem cell identification, squamous cell carcinoma of the larynx, respiratory syncytial virus, and transitional cell carcinomas of the human urinary tract. Anti-Cytokeratin 17 antibody (E3) is an essential tool for researchers studying these critical biological processes and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 17 Antibody (E3) References:

1. Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature.  |  Ikeda, K., et al. 2008. Gynecol Oncol. 108: 598-602. PMID: 18191996
2. Cytokeratin 17 immunoexpression in actinic keratosis (bowenoid and nonbowenoid) and in Bowen disease.  |  Fernandez-Flores, A. 2016. Ann Diagn Pathol. 20: 1-6. PMID: 26740287
3. Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma.  |  Kim, K., et al. 2017. Appl Immunohistochem Mol Morphol. 25: 346-350. PMID: 26990743
4. Stem Cell Markers (Cytokeratin 17 and Cytokeratin 19) in Scarring and Nonscarring Alopecia.  |  El Sakka, D., et al. 2016. J Cutan Aesthet Surg. 9: 165-171. PMID: 27761086
5. Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.  |  Hamed, MA., et al. 2017. Clin Exp Otorhinolaryngol. 10: 213-220. PMID: 28073243
6. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance.  |  Dundr, P., et al. 2022. Virchows Arch. 481: 201-212. PMID: 35554675
7. Diagnostic Utility of Cytokeratin 17 Expression in Oral Squamous Cell Carcinoma: A Review.  |  Gyanchandani, A., et al. 2022. Cureus. 14: e27041. PMID: 35989819
8. Use of Cytokeratin 17 in the Differentiation Between Desmoplastic Trichilemmoma and Cutaneous Basal Cell Carcinoma.  |  Chaudet, KM., et al. 2022. Am J Dermatopathol. 44: 886-890. PMID: 36197047
9. Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients.  |  Bălănescu, P., et al. 2022. Biochem Med (Zagreb). 32: 030707. PMID: 36277429
10. Exploring the role of cytokeratin 17 in skin tumorigenesis and human papillomavirus persistence.  |  de Brito, M. and O'Toole, EA. 2024. Br J Dermatol. 191: 862-863. PMID: 39049691

The preferred Cytokeratin 17 antibody is Cytokeratin 17 Antibody (E-4): sc-393002.